Skip to main content

Volume 16 Supplement 1

1st Joint ANIRCEF-SISC Congress

  • Poster presentation
  • Open access
  • Published:

P053. An Italian study on the actual cost/benefit of onabotulinumtoxinA (BT-A) in chronic migraine: preliminary results


In Italy, the estimated cost of chronic migraine (CM) is around six billion euros per year (Agenas, 2011) considering the health costs, the loss in working productivity and quality of life.

The efficacy of BT-A in the prophylactic treatment of CM has been demonstrated [1]. However, BT-A therapy is expensive and the limited health service resource may raise the question of the cost/benefit ratio. Ruggeri et al[1] carried out a study to provide an estimate of the incremental cost-effectiveness ratio of the treatment of CM with BT-A 2 . They compared the benefit as extrapolated from the PREEMPT data with those of a population of CM from the METEOR study, as well as with those of an actual population of CM from a district of Rome[1]. In the present study we compared actual costs and benefit in a CM population before and after BT-A treatment.


We recruited CM patients with or without MOH, according to the ICHD-3beta classification. All patients were injected using the standard protocol for CM. At follow-ups, planned every 12 weeks, headache clinical features (including quality of life scales), direct health costs and indirect costs due to loss of work productivity[1] supported within 3 months, were recorded.


We consecutively enrolled 34 patients with CM, (19 with MOH). To date, we have considered the results at 24 weeks (T2). Nine patients (26%) dropped out because of side effects or poor compliance (5 at T1, 4 at T2). In the nineteen patients, who completed the T2 follow-up (56%), we observed a statistical clinical benefit (p < 0.001) in headache features (29% less in attack frequency, 39% less in attack duration, 21% less in pain intensity, 63% less in drug intake) and a significant reduction of pain-killer costs per month (-75%) and a decrease of working productivity loss (-28%). Moreover, MSQ and MIDAS were also significantly improved.


After the first 24 weeks, BT-A was effective in both clinical CM features, as well as the decrease of the amount of its direct and indirect health costs. These preliminary data seem to confirm the findings from studies of probabilistic estimates although they will need to be confirmed in a larger population and a longer follow-up.

Written informed consent to publication was obtained from the patient(s).


  1. Ruggieri M, Carletto A, Marchetti M: Cost effectiveness of onabotulinumtoxinA for prophylaxis of chonic migraine. Pharmaecon Ital Res Artic. 2013, 15: 19-33. 10.1007/s40276-013-0003-5.

    Article  Google Scholar 

  2. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ: Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010, 50 (9): 1406-18. 10.1111/j.1526-4610.2010.01766.x.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Barbara Petolicchio.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Petolicchio, B., Toscano, M., Squitieri, M. et al. P053. An Italian study on the actual cost/benefit of onabotulinumtoxinA (BT-A) in chronic migraine: preliminary results. J Headache Pain 16 (Suppl 1), A112 (2015).

Download citation

  • Published:

  • DOI: